Results for the follow-up of the RESPONSE study
The stories behind the advances in polycythemia vera
MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia
What's new in myeloproliferative neoplasms?
Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera